RE:RE:RE:AACR 2024 : Cancer vaccines get reintroduction with pathway April 07, 2024 - AACR 2024 highlights - Immune response to cancer vaccine for pancreatic cancer continue to correlate with clinical benefit.
The mRNA vaccine autogene cevumeran in combination with Roche's atezolizumab and modified Folfirinox led to the expansion of multiple CD8+ T cell clones in the eight responding patients—98% of which were not present in blood, tumors, or adjacent tissue prior to vaccination. Over 80% of the expanded CD8+ T cell clones persisted in the blood long-term at substantial fractions (median 0.1% of all blood T cells).
“Our data indicate that autogene cevumeran can induce CD8+ T cells with significant longevity, substantial magnitude, and durable function,” summarized Balachandran, a surgical oncologist and member of the David M. Rubenstein Center for Pancreatic Cancer Research at Memorial Sloan Kettering Cancer Center.
“The findings that individualized neoantigen-specific cancer vaccines can induce a robust immune response that correlates with delayed disease recurrence continues to support these vaccines as an encouraging therapeutic approach for pancreatic cancer.”
And so by extension, is ONCY's drug platform pelareorep in the treatment of the more serious condition of Stage 4 advanced/metastatic PDAC when sequentially implemented to work in combination with an immune checkpoint inhibitors plus the chemotherapy n-paclitaxel, as ONCY's Phase 2 GOBLET-1 mPDAC cohort study is demonstrating.
https://www.aacr.org/about-the-aacr/newsroom/news-releases/immune-response-to-investigational-rna-vaccine-for-pancreatic-cancer-continues-to-correlate-with-clinical-benefit/